Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Britain Courts Anthropic Amid US Defense Department Dispute 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
SAN DIEGO, July 31, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that management will present an update on Obalon at the following upcoming investor conference:
- Andy Rasdal, Chief Executive Officer and Bill Plovanic, Chief Financial Officer of Obalon will present an update on the company at the Canaccord Genuity Growth Conference in Boston, MA on Wednesday, August 9, 2017 at 9:30 am (ET). The presentation, which will occur live at the Intercontinental Hotel, will be concurrently webcast.
The link to the webcast will be available at: http://wsw.com/webcast/canaccord26/obln. A replay of the webcast will be available for 90 days following the presentation.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 [email protected]
